Omar Al Asad, MD
Medical Oncology · New Haven, CTNPI 1447505110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $340, 3.2 times the $106 reported in 2023. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.
Across 26 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$99
- AbbVie$96
- Novartis$60
- Servier Pharmaceuticals LLC$49
- Gilead$41
- Bristol Myers Squibb$38
- plus $153 from 7 others
What the payments were for
- Food & beverage$536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| AbbVie | 3 | $96 |
| Novartis | 3 | $60 |
| Servier Pharmaceuticals LLC | 3 | $49 |
| Gilead | 2 | $41 |
| Bristol Myers Squibb | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Pfizer | 1 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Genmab U.S., Inc. | 1 | $18 |
How this compares
$536 in reported general payments places this provider in the 40th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 13 | $195,795 |
| Lenalidomide | 12 | $189,500 |
| Abiraterone Acetate | 38 | $111,124 |
| EliquisApixaban | 42 | $25,239 |
| XareltoRivaroxaban | 11 | $5,848 |
| Anastrozole | 76 | $1,192 |
| Acyclovir | 27 | $665 |
| Potassium Chloride | 59 | $515 |
| Ondansetron Hcl | 49 | $393 |
| Prochlorperazine Maleate | 41 | $348 |
| Tamoxifen Citrate | 13 | $244 |
| Prednisone | 64 | $203 |
| Warfarin Sodium | 18 | $188 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $158 |
| Dexamethasone | 20 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $25,23942 claims |
| Johnson & JohnsonXarelto | $18 | $5,84811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 medical oncology providers in Connecticut.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
- Howard HochsterNew Haven$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.